Evidence map›Paper›PMID 30309687›Full record

ArticleEuropean urology2019

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

H Ballentine Carter, Brian Helfand, Mufaddal Mamawala, Yishuo Wu, Patricia Landis, Hongjie Yu, Kathleen Wiley, Rong Na, Zhuqing Shi, Jacqueline Petkewicz and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05295407 (Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy), which is not on this map. Cited by 98 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 3 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05295407 recruitingnot on this mapstarted 2021, after this paper: background citation

Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)

Typeobservational_patient_registrySponsorEndeavor HealthRan2021 to 2027Enrolled1,000ConditionsProstate CancerArmsGenetic Assessment
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 3 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

H Ballentine CarterDepartment of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: hcarter@jhmi.edu.
Brian HelfandProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA; Department of Surgery, North Shore University Health System, Evanston, IL, USA.
Mufaddal MamawalaDepartment of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yishuo WuProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Patricia LandisDepartment of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hongjie YuProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA.
Kathleen WileyDepartment of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rong NaProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA; Department of Urology, Ruijin Hospital, Jiaotong University, Shanghai, China.
Zhuqing ShiProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China.
Jacqueline PetkewiczDepartment of Surgery, North Shore University Health System, Evanston, IL, USA.
Sameep ShahProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA.
Richard J FantusProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA; University of Chicago, Evanston, IL, USA.
Kristian NovakovicDepartment of Surgery, North Shore University Health System, Evanston, IL, USA.
Charles B BrendlerProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA.
S Lilly ZhengProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA.
William B IsaacsDepartment of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jianfeng XuProgram for Personalized Cancer Care, North Shore University Health System, Evanston, IL, USA; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China.
NorthShore University HealthSystem · USJohns Hopkins Medicine · USJohns Hopkins University · USHuashan Hospital · CN

Funding

Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
NCI NIH HHS P50 CA180995
6 · The paper itself

Abstract

backgroundMutations in DNA repair genes are associated with aggressive prostate cancer (PCa).

objectiveTo assess whether germline mutations are associated with grade reclassification (GR) in patients undergoing active surveillance (AS). DESIGN, SETTING, AND

participantsTwo independent cohorts of PCa patients undergoing AS; 882 and 329 patients from Johns Hopkins and North Shore, respectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Germline DNA was sequenced for DNA repair genes, including BRCA1/2 and ATM (three-gene panel). Pathogenicity of mutations was defined according to the American College of Medical Genetics guidelines. Association of mutation carrier status and GR was evaluated by a competing risk analysis. RESULTS AND LIMITATIONS: Of 1211, 289 patients experienced GR; 11 of 26 with mutations in a three-gene panel and 278 of 1185 noncarriers; adjusted hazard ratio (HR)=1.96 (95% confidence interval [CI]=1.004-3.84, p=0.04). Reclassification occurred in six of 11 carriers of BRCA2 mutations and 283 of 1200 noncarriers; adjusted HR=2.74 (95% CI=1.26-5.96, p=0.01). The carrier rates of pathogenic mutations in the three-gene panel, and BRCA2 alone, were significantly higher in those reclassified (3.8% and 2.1%, respectively) than in those not reclassified (1.6% and 0.5%, respectively; p=0.04 and 0.03, respectively). Carrier rates for BRCA2 were greater for those reclassified from Gleason score (GS) 3+3 at diagnosis to GS ≥4+3 (4.1% vs 0.7%, p=0.01) versus GS 3+4 (2.1% vs 0.6%; p=0.03). Results are limited by the small number of mutation carriers and an intermediate end point.

conclusionsMutation status of BRCA1/2 and ATM is associated with GR among men undergoing AS. PATIENT SUMMARY: Men on active surveillance with inherited mutations in BRCA1/2 and ATM are more likely to harbor aggressive prostate cancer.

Indexed as

Genes, BRCA1Genes, BRCA2AgedAtaxia Telangiectasia Mutated ProteinsDNA Mutational AnalysisGerm-Line MutationHumansMaleMiddle AgedNeoplasm GradingProstatic NeoplasmsWatchful WaitingAtaxia Telangiectasia Mutated ProteinsATM protein, humanActive surveillanceATMBRCA1BRCA2Germline mutations

Identifiers

PMID30309687
PMCPMC6699614
OpenAlexW2897403465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.